BioCardia, Inc. Receives Nasdaq Delisting Notice Due to Stockholders’ Equity Deficiency

Key Points from the BioCardia, Inc. 8-K Filing

• Delisting Notice Received: BioCardia, Inc. (“the Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) on April 10, 2026.
• Reason for Notice: The Company’s stockholders’ equity as of December 31, 2025 was \$895,000, which is below the Nasdaq Capital Market minimum requirement of \$2.5 million under Nasdaq Listing Rule 5550(b)(1).
• Compliance Deadline: BioCardia has until May 25, 2026 to submit a plan to Nasdaq outlining how it intends to regain compliance with the listing requirement.
• Potential Extension: If Nasdaq accepts the Company’s plan, it may grant an extension of up to 180 calendar days from April 10, 2026 for BioCardia to evidence compliance.
• Immediate Effect: The notice does not immediately affect the listing or trading of BioCardia’s common stock. The shares will continue to trade on the Nasdaq Capital Market under the symbol “BCDA”.

Important Information for Shareholders

• Risk of Delisting: If BioCardia fails to regain compliance by the deadlines, or if Nasdaq does not accept its remediation plan, there is a risk that BioCardia’s shares could be delisted from Nasdaq. Delisting often results in reduced liquidity, reduced investor interest, and may negatively impact share price.
• Remediation Plan: The Company intends to submit a compliance plan to Nasdaq. If the plan is not accepted, BioCardia may request a hearing to present its plan to a Nasdaq Hearings Panel.
• Forward-Looking Uncertainties: The Company warns that there is no assurance it will be able to submit a plan that Nasdaq will accept, regain compliance, or receive any relief from delisting. This uncertainty is material and could have a significant effect on shareholder value.
• Stockholder Equity Situation: The current equity deficit underscores the Company’s financial challenges and could impact its ability to raise capital, attract institutional investors, and maintain market confidence.

Potential Share Price Impact

The risk of delisting is a material event for shareholders. Delisting could have a negative impact on share price due to reduced liquidity and investor confidence. Conversely, successful remediation and compliance could positively affect share value. Investors should closely monitor the Company’s actions and Nasdaq’s response over the coming months.

Leadership and Contact Information

• President and CEO: Peter Altman, Ph.D.
• Business Address: 320 Soquel Way, Sunnyvale, CA 94085
• Trading Symbol: BCDA
• Exchange: Nasdaq Capital Market

Forward-Looking Statements

Aside from factual statements, the report contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. These involve risks, uncertainties, and assumptions that are difficult to predict. There is no guarantee that the Company will regain compliance or avoid delisting.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to review BioCardia, Inc.’s filings with the Securities and Exchange Commission and consult with a qualified financial advisor before making any investment decisions. The information herein is based on the Company’s SEC filings as of April 10, 2026, and may be subject to change.

View BioCardia, Inc. Historical chart here